Core Insights - VivoSim Labs, Inc. is presenting new data on its NAMkind™ liver and intestine models at the Society of Toxicology meeting, demonstrating their ability to predict toxicity and side effects of antibody drug conjugates (ADCs) [1][4] Group 1: Company Overview - VivoSim Labs, Inc. specializes in next-generation New Approach Methodologies (NAMs) for preclinical safety, focusing on testing drugs in 3D human tissue models of the liver and intestine [7] - The company operates from San Diego, CA, and is expanding its services globally, including in the US, Europe, Korea, and China [6][7] Group 2: Product and Technology - The NAMkind™ models can provide insights into target engagement, premature linker cleavage, and bystander effects in complex human cell models [3] - Testing of approved ADC therapies in NAMkind™ models has shown a close correlation with clinical results, particularly regarding liver toxicity and intestinal side effects [4][5] Group 3: Market Potential and Demand - With hundreds of ADCs in development globally, the NAMkind™ models are positioned as a powerful tool to mitigate off-target toxicity and enhance drug candidate selection [2] - The FDA's announcement to refine animal testing requirements in favor of NAM methods is expected to accelerate the adoption of these human tissue models [7]